CL insider purchase: 289 shares via deferred retainer at $82.13

Rhea-AI Filing Summary

John P. Bilbrey, a director of Colgate-Palmolive Company (CL), reported an acquisition on 10/01/2025 of 289 shares of the issuer's common stock at a price of $82.13 per share. Following the transaction, Mr. Bilbrey directly beneficially owns 36,658 shares and indirectly owns 4,719 shares through a trust. The filing states the reason for the acquisition: a portion of his annual cash retainer was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors, resulting in the issuance of common stock.

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025. No derivative transactions, dispositions, or other changes are disclosed in this Form 4.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BILBREY JOHN P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	289	$82.13	$24K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 36,658 shares (Direct); Common Stock — 4,719 shares (Indirect, By Trust)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BILBREY JOHN P

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A(1)		289	A	$82.13	36,658	D
Common Stock								4,719	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors.

	/s/ Kristine Hutchinson, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Colgate-Palmolive director John P. Bilbrey report (CL)?

He reported an acquisition of 289 common shares on 10/01/2025 at $82.13 per share.

How many Colgate-Palmolive shares does John P. Bilbrey own after the reported transaction?

He directly owns 36,658 shares and indirectly owns 4,719 shares through a trust.

Why were the shares acquired by the director?

The filing states the shares resulted from a portion of his annual cash retainer being deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.

When was the Form 4 filed and who signed it?

The Form 4 lists the transaction date as 10/01/2025 and was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.

Were there any derivative securities or dispositions reported in this Form 4 for CL?

No; the filing shows only the non-derivative acquisition of common stock and does not report derivative transactions or dispositions.